Brief: Ligand Pharmaceuticals Q2 EPS USD -2.88
06/08/2024 21:01
Aug 06 (Reuters) - Ligand Pharmaceuticals Q2 basic EPS USD -2.88. * Q2 operating income USD -19.1 million * Q2 net income continuing operations USD -51.911 million * Q2 pretax profit USD -65.39 million
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan